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Abstract
Objective: The primary purpose of this study was to examine the construct validity of a continuous metabolic
syndrome score (cMetS) in children. The secondary purpose was to identify a cutpoint value(s) for an adverse
cMetS based on receiver operating characteristic (ROC) curve analysis.
Methods: 378 children aged 7 to 9 years were assessed for the metabolic syndrome which was determined by
age-modified cutpoints. High-density-lipoprotein cholesterol, triglycerides, the homeostasis assessment model of
insulin resistance, mean arterial pressure, and waist circumference were used to create a cMetS for each subject.
Results: About half of the subjects did not possess any risk factors while about 5% possessed the metabolic
syndrome. There was a graded relationship between the cMetS and the number of adverse risk factors. The cMetS
was lowest in the group with no adverse risk factors (-1.59 ± 1.76) and highest in those possessing the metabolic
syndrome (≥3 risk factors) (7.05 ± 2.73). The cutoff level yielding the maximal sensitivity and specificity for
predicting the presence of the metabolic syndrome was a cMetS of 3.72 (sensitivity = 100%, specificity = 93.9%,
and the area of the curve = 0.978 (0.957-0.990, 95% confidence intervals).
Conclusion: The results demonstrate the construct validity for the cMetS in children. Since there are several
drawbacks to identifying a single cut-point value for the cMetS based on this sample, we urge researchers to use
the approach herein to validate and create a cMetS that is specific to their study population.
Introduction
The constellation of adverse cardiovascular disease
(CVD) and metabolic risk factors, which include ele-
vated abdominal obesity, blood pressure, glucose, and
triglycerides (TG) and lowered high-density lipoprotein-
cholesterol (HDL-C), has been termed the metabolic
syndrome [1]. Based on the National Cholesterol Educa-
tion Program Adult Treatment Program III (ATP II) cri-
teria [1] and the International Diabetes Foundation
criteria [2] approximately 35% and 39%, respectively, of
U.S. adults possess the metabolic syndrome [3]. In
terms of health outcomes, the metabolic syndrome is
associated with an increased risk of all-cause mortality,
CVD morbidity and mortality, type 2 diabetes, and some
cancers [4].
In 1980, Khoury et al. [5] were perhaps the first to
show the clustering of CVD risk factors in 6-19 yr old
subjects of the Cincinnati Lipid Research Clinic’s
Princeton Study. In 1987, Smoak et al. [6] also reported
the clustering of CVD risk factors in the Bogalusa Heart
Study. However, not until the recent medicalization and
coining of the term ‘metabolic syndrome’ had reports
indicated the emergence of the metabolic syndrome dur-
ing childhood and adolescence [7-11]. Data from the
United States (U.S.) National Health and Nutrition
Examination Survey (NHANES) III (1988-1994) showed
that the prevalence rate of the metabolic syndrome was
4% in 12-19 yr old adolescents and 30% in obese adoles-
cents [11]. The prevalence rate increased to 6% (>2 mil-
lion) in NHANES 1999-2000 [10]. Another paper using
the same data (i.e., NHANES III) but different criteria
showed that the prevalence rate was nearly 10% [12].
Among 7-to-9 yr old children residing in a rural Mid-
western US state, the prevalence rate was 5% [9]. Preva-
lence rates in children and adolescents have been
reported to be 6.5% in northern Mexico [13], 9% in
Korea [14], 2% in Turkey [15], and 10% in Quebec,
Canada [16]. * Correspondence: jce@msu.edu
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syndrome in children or adolescence and the prevalence
rate is relatively low, several authors [17-27] have
derived a continuous score representing a composite
CVD/metabolic risk factor profile or index (i.e., the
metabolic syndrome score) which has been recom-
mended in a joint statement by the American Diabetes
Association and the European Association for the Study
of Diabetes [28]. Previous procedures to derive the score
include principal component analysis [21,22], Z scores
[17,18,21,23-26], and centile rankings [19,20]. However,
the validity of these composite scores in children and
adolescents has not been examined. A recent paper in
adults [29] showed a continuous metabolic syndrome
score (cMetS) derived from principal component analy-
sis was higher in adults with the metabolic syndrome
and that the score increased progressively with increas-
ing number of adverse risk factors.
Besides validating the cMetS, another related issue is
identifying the cMetS that confers increased risk of the
metabolic syndrome. In other words, what is the ‘opti-
mal’ cutoff for interpreting the extent of the cMetS?
Recently, receiver operating characteristics (ROC) analy-
sis has been used to determine waist circumference and
insulin resistance cutoff values for identifying the meta-
bolic syndrome in youth [30,31]. Based on the increased
use and utility of the cMetS in pediatric epidemiological
research, the primary purpose of this study was to
examine the construct validity of a cMetS in children.
The secondary purpose was to identify a cutoff for an
adverse cMetS based on ROC analysis.
Methods
Subjects
The participants used for this study were part of a phy-
sical activity intervention in eastern Kansas called “Phy-
sical Activity Across the Curriculum” (PAAC). It should
be emphasized that data analysis in this paper is based
on baseline measures prior to the intervention. A sub-
sample of 2
nd and 3
rd grade children (ages 7-9 years
old) from each school were recruited for additional
baseline testing. Inclusion into the sub-sample consisted
of the following: 1) both the parent and child gave their
written consent and assent, respectively, to participate in
baseline testing in accordance with the Human Subjects
Committee at the university; 2) the child had to partici-
pate in all of the tests (i.e., the child could not choose
which tests to complete); and 3) the child did not have
insulin dependent diabetes, cardiovascular disease, or
any other disease that limited physical activity participa-
tion. A total of 852 children volunteered for the addi-
tional testing. Due to time constraints all the children
could not participate; therefore, a random sample of 495
of these volunteers was selected to participate in the
baseline testing. We compared data on the children who
signed up to participate but were not randomized to the
sub-sample to the 495 selected for subsample data col-
lection. There were no significant differences in weight
(p = 0.208) height (p = 0.7523), or BMI (p = 0.1856).
T h e r ew e r em o r em a l e s( 4 7 %v s . 3 5 % ) ,b l a c k s( 7v s .2 % )
and Hispanics (10 vs. 4%) in the subsample than those
not selected. The differences for gender and race were
purposeful since we over-sampled boys and non-whites
to ensure a distribution that was similar to the schools.
Of the 495 children that were randomly selected to
participate in the baseline testing, 35 did not participate
due to absences on the testing day, 9 ate the morning of
the blood draw, 8 did not have height and weight data,
and 81 had incomplete blood data, leaving 378 children
(194 females, 184 males) (272 White, 42 Hispanic, 23
African-American, 9 Asian, 5 Native American, 1 Pacific
Islander, 16 more than one race, 10 unknown or not
reported) with complete data for statistical analysis.
Sample bias was not present, as demographic character-
istics were similar between those children who were
either included or excluded from the data analyses.
Measures of the components of the metabolic syndrome
Waist circumference (WC) was measured in duplicate to
the nearest 0.1 cm using a Gullick tape measure at the
smallest girth around the trunk in the horizontal plane
underneath the participant’s clothing. There was no dif-
ference for inter-tester reliability for waist circumference
and the coefficient of variation was 1.65%. Resting blood
pressure was measured in duplicate by a trained person-
nel using a random-zero sphygmomanometer (Hawksley
& Sons Ltd., England) according to standard methods
[32]. To determine the appropriate cuff size the child’s
arm circumference was measured. Children rested
quietly for 5 minutes prior to measurement. The first
and fifth Korotkoff sounds were recorded as systolic and
diastolic blood pressure, respectively. Mean arterial pres-
sure (MAP) was calculated using the following formula:
MAP = ((systolic blood pressure-diastolic blood pres-
sure)/3)) + diastolic blood pressure). Inter-tester reliabil-
ity for systolic or diastolic blood pressure was similar
and the coefficient of variation for both measures was
5.3%. Blood samples were collected by a trained phlebo-
tomist after an 8-hour fast using standard venipuncture
methods. Blood samples were then processed at the
study site by centrifuging the samples, placing the
serum in pre-labeled vials, storing the samples at -70°C,
and shipping the samples to the University of Colorado,
Health Sciences Center, Denver, CO for further proces-
sing. Blood samples remained stored at -70°C until ana-
lyses were conducted. Glucose, total cholesterol, and
triglyceride concentrations were measured enzymatically
using a Cobas Mira Chemistry System (Roche Diagnos-
tic Systems, Indianapolis, IN). High-density-lipoprotein
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enzymatically using a Cobas Mira Chemistry System
(Diagnostic Chemicals Ltd, Oxford, CT). Insulin levels
were measured using a radioimmuno assay (Diagnostic
Systems Laboratory, Webster, TX). Homeostasis model
assessment (HOMA), an indicator of insulin resistance,
was calculated as fasting insulin (uU/ml) * fasting glu-
cose (mg/dl)/22.5. The coefficient of variation for all
blood measurements was <5% for both inter- and intra-
assay quality control.
Classification of the MetS
Presence of the metabolic syndrome was determined by
the age-modified cutpoints of the ATP III metabolic
syndrome criteria published previously by Cook et al
[11]. Subjects with three or more of the following five
risk factors were defined as having the metabolic syn-
drome: 1) triglycerides ≥1 1 0m g / d l( 1 . 1 3m m o l / l ) ,2 )
HDL cholesterol ≤40 mg/dl (1.04 mmol/L), 3) systolic
and/or diastolic blood pressure ≥ 90th percentile for
age, sex, and height, based onp u b l i s h e dr e f e r e n c ed a t a
[33], 4) fasting plasma glucose ≥110 mg/dl (6.10 mmlo/
l), and 5) WC ≥ 90th percentile for age and sex from
this sample. The dichotomous metabolic syndrome vari-
able (yes/no) was used in the ROC analysis (see statisti-
cal analysis).
Derivation of the continuous MetS score
The inclusion of the key components (i.e., glucose,
lipids, blood pressure, and adiposity) is supported by the
results of factor analysis in children and adolescents
[16,34-36] which shows the underlying patterns or
structure among variables showing high degrees of
inter-correlation. Thus, there are common variables that
can be used to calculate a cMetS. The cMetS was
derived by first standardizing the individual cMetS vari-
ables (WC, MAP, HOMA, HDL-C, and TG) by regres-
sing them onto age, sex, and race to account for any
age-related differences and sex and race differences. The
standardized HDL-C was multiplied by -1 since it is
inversely related to metabolic risk. The standardized
residuals (Z-scores) for WC, MAP, HDL-C, triglyceride,
and HOMA were summed to create the cMetS. These
variables were chosen since they represent the same
variables (except blood glucose) used in the widely-used
National Cholesterol Education Program Adult Treat-
ment Panel III [1] and International Diabetes Federation
[2] adult clinical criteria for the metabolic syndrome.
HOMA was chosen instead of glucose since most chil-
dren possess normal fasting glucose and HOMA is
related to sophisticated measures of insulin resistance
[37]. MAP was used since including both systolic and
diastolic would load two blood pressure variables into
the calculation, and MAP represents both systolic and
diastolic blood pressure. A higher cMetS indicates a less
favorable metabolic profile.
Statistical analysis
The percentage of subjects with varying number of
adverse risk factors was calculated by sex and for the
total sample. Descriptive statistics for physical character-
istics and the individual risk factors were calculated by
the number of adverse risk factors (0, 1, 2, 3+) and the
total sample. The primary purpose of the study was
examined by testing for differences in the cMetS across
the number of adverse risk factors (0, 1, 2, 3+) using
analysis of variance. For the secondary purpose of the
study, ROC analysis was utilized to determine cutoff
values that minimize the total number of misclassifica-
tion errors and to provide an evaluation of the global
performance of the cMetS to discriminate between
those with or without the MetS. ROC analysis evaluates
the performance of any continuous variable to discrimi-
nate between two mutually exclusive states of disease
[38-40]. By using ROC, information about the agree-
ment of the tests will be provided along with suggested
cutpoints for the cMetS. ROC provides measures of sen-
sitivity (Se), specificity (Sp), and the area under the ROC
curve (AUC). Se can be defined as the probability of a
positive test outcome in an individual who possesses
MetS (true-positive) and Sp as the probability of a nega-
tive test outcome in an individual without MetS (true-
negative). Se and Sp are inversely related depending on
the cutpoint and indicate local performance of the
recommended cutpoint. The optimal cutoff can be iden-
tified as the value where the sum of Se and Sp are maxi-
mized. ROC analysis involves the plotting of a curve
representing the diagnostic Se (true positive rate) and 1
- Sp (false-positive rate) across a wide range of cutoff
values using a diagnostic test (in this case, based on
MetS status). The area under this curve can be utilized
as a measure of the global accuracy of a diagnostic test
[40]. More specifically, AUC relates to the overall ability
of using the cMetS to discriminate between those with
and without MetS. In this analysis, AUC can be consid-
ered equivalent to the probability that a randomly
drawn individual from the MetS reference has a higher
cMetS than a child randomly drawn from the non-MetS
sample. It has been suggested that the AUC be inter-
preted according to the following guidelines: non-infor-
mative/test equal to chance (AUC = 0.5), less accurate
(0.5 < AUC ≤ 0.7), moderately accurate (0.7 < AUC ≤
0.9), highly accurate (0.9 < AUC ≤ 1.0), and perfect dis-
criminatory tests (AUC = 1.0) [41].
Results
Table 1 shows the number and percentage of subjects
by the number of adverse risk factors. Overall, about
half of the subjects did not have any adverse risk factors
and in turn, the other half possessed at least 1 adverse
risk factor. About 5% possessed the metabolic syndrome
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risk factors. There were no significant sex differences in
the % of subjects possessing a given number of adverse
risk factors or in the occurrence of any given risk factor.
Elevated BP was the most common risk factor (37%)
and abnormal fasting glucose was the least common
(1%)(Table 2). Although not included as a component of
the MetS, it should be notedt h a t4 4 %o ft h es a m p l e
was either overweight or obese.
Descriptive statistics for the physical characteristics
and individual risk factors by the number of adverse risk
factors are presented in Table 2. As would be expected
based on the definition of the MetS, there was a general
trend for those with more adverse risk factors to be big-
ger and possess more adverse levels of the risk factors.
Figure 1 shows the graded relationship between the
cMetS and the number of adverse risk factors. The
cMetS is lowest in the group with no adverse risk fac-
tors (-1.59 ± 1.76) and highest in those possessing the
metabolic syndrome (≥3r i s kf a c t o r s )( 7 . 0 5±2 . 7 3 ) .T h e
mean cMetS for the total sample is 0.00 ± 3.0.
According to the ROC curve analysis (Figure 2), the
cutoff level yielding the maximal sensitivity and specifi-
city for predicting the presence of the metabolic syn-
d r o m ew a sac M e t So f3 . 7 2 .T h es e n s i t i v i t ya n d
specificity using this cutoff value were 100% and 93.9%,
respectively. The AUC was 0.978 (0.957-0.990, 95% con-
fidence intervals) (p < 0.001). Other cutpoint values and
their corresponding sensitivity and specificity are pro-
vided in Table 3 for interpretation by the reader.
Discussion
As previously shown in this sample [9], approximately
5% of 7-9 yr olds possess the metabolic syndrome based
on the criteria of Cook et al. [11]. Again, it should be
emphasized that there is no universal definition of the
metabolic syndrome in children and adolescents and
that the prevalence is relatively low. Thus, both of these
factors limit the ability to conduct epidemiological stu-
dies examining various genetic and environmental risk
factors for the metabolic syndrome or the clustering of
risk factors in youth. Therefore, we [23-26,42] and
others [17,18] have constructed a cMetS for investiga-
tions in pediatric epidemiology and medicine. An
advantage to a cMetS is that it is statistically more sen-
sitive and less error prone by comparison to the dichot-
omous approach [18,43]. Several researchers have
utilized the cMetS in pediatric epidemiological research.
For example, results from the Corpus Christi Child
Heart Study indicated higher cMetS in Mexican-Ameri-
can boys and girls compared to White boys and girls
[21]. Recent studies also show that habitual physical
activity and aerobic fitness are inversely associated with
the cMetS [17,18,23,24,26,42], and that aerobic fitness
attenuates the cMetS among high fat children and ado-
lescents [24,26,42]. The cMetS has also been shown to
track from childhood/adolescence into young adulthood
[19,20,22,25]. This latter finding holds importance to the
predictive utility of the cMetS on adult disease
outcomes.
To date, this is the first study to validate the cMetS
score in children. The results indicate a clear graded
relationship between the cMetS and the number of
adverse risk factors with those possessing ≥3 risk factors
(i.e., metabolic syndrome) having the highest cMetS.
Furthermore, results of the ROC analysis identified a
cMetS of 3.72 as the optimal cutpoint which confers an
increased risk of MetS in this sample of 7-9 year old
children. The AUC for this index was 98%, which indi-
cates a cMetS of 3.72 is highly accurate at detecting the
presence of MetS in this sample. The sensitivity and
specificity using this cutoff value were 100% and 93.9%,
respectively. In other words, none of the children with
metabolic syndrome had a cMetS score lower than 3.72
and only 6% of the children without metabolic syn-
drome had a score higher than 3.72. This cutoff value
also approximates the mean value for subjects posses-
sing 2 adverse risk factors (Table 2). However, other
cMetS indicated in Table 3 should also be considered
since they also possess high values for sensitivity and
specificity. It should also be considered that there may
be varying levels of increased risk for MetS (e.g., low,
moderate, high) based on the cMetS, particularly since
other scores showed good sensitivity and specificity.
Hence, cMetS can be used as a preventative measure
rather than a diagnostic tool. However, it is important
to note that there are several drawbacks to identifying
cut-point value(s) for the cMetS based on this sample,
Table 1 Percentage of adverse components of the metabolic syndrome in boys and girls.
# of risk factors Boys (n/%) N = 184 Girls (n/%) N = 194 Total sample (n/%) N = 378
0 101 (54.5%) 91 (46.9%) 192 (50.7%)
1 62 (33.7%) 68 (35.0%) 130 (34.4%)
2 12 (6.5%) 26 (13.4%) 38 (10.0%)
3 8 (4.3%) 7 (3.6%) 15 (4.0%)
4 1 (0.5%) 2 (1.0%) 3 (0.8%)
5 0 (0%) 0 (0%) 0 (0.0%)
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to validate and create a cMetS that is specific to their
study population. Some of these limitations are dis-
cussed below. First, the cMetS is sample-specific. Sec-
ond, the cut-off points used herein, e.g., the Cook
criteria does not have a solid clinical or health-related
outcome basis. Third, the cMetS is based upon the
assumption that each selected variable is equally
important in defining CVD risk, although a child’s being
defined as at risk does not necessarily mean that the
child has high levels of CVD risk factors per se.
A similar study in adults has also validated the cMetS.
In a randomly selected sample of 18- to 75-year-old
(mean age = 46 yrs) Flemish adults (571 men and 449
women), the cMetS, determined by principal component
analysis, was significantly higher in subjects with cMetS
as defined by the International Diabetes Federation
(men [12.8%]: 2.03 ± 1.00, women [>8.5%]: 2.63 ± 1.28)
Table 2 Physical characteristics of the total sample and by the number of adverse risk factors.
Number of risk factors
0 1 2 3+ Total sample
N 192 130 38 18 378
Age (yrs) 7.7 (0.7) 7.7 (0.7) 7.9 (0.6) 7.7 (0.5) 7.7 (0.6)
Height (cm) 129.7 (6.5) 129.6 (6.4) 133.2 (6.0) 135.0 (7.7) 130.3 (6.6)
Mass (kg) 28.2 (4.6) 29.7 (6.3) 38.4 (10.0) 46.4 (14.6) 30.6 (8.1)
BMI (kg/m
2) 16.7 (1.7) 17.6 (2.8) 21.4 (4.3) 25.0 (4.7) 17.9 (3.4)
% overweight - - - - 21%
% obese - - - - 23%
Body fat (%) 17.5 (5.5) 19.4 (6.8) 27.3 (8.4) 35.6 (9.8) 20.0 (7.9)
WC (cm) 56.9 (4.3) 58.2 (6.6) 66.8 (10.5) 78.6 (13.4) 59.4 (8.4)
% elevated WC - - - - 10%
SBP (mm Hg) 101.1 (7.2) 109.1 (10.0) 111.8 (9.0) 116.0 (7.3) 105.6 (9.7)
DBP (mm Hg) 63.2 (5.4) 70.7 (8.0) 73.6 (8.8) 73.7 (9.6) 67.4 (8.2)
% elevated BP - - - - 37%
MAP (mm Hg) 75.8 (4.9) 83.5 (7.0) 86.4 (7.2) 87.8 (7.4) 80.1 (7.5)
Glucose (mg/dl) 78.3 (7.0) 80.8 (6.3) 80.4 (12.0) 81.1 (8.4) 79.5 (7.6)
% elevated glucose - - - - 1%
Insulin (uU/ml) 5.5 (5.0) 7.6 (8.2) 11.0 (12.2) 12.3 (11.0) 7.1 (7.7)
HOMA 1.08 (1.07) 1.55 (1.77) 2.44 (3.65) 2.52 (2.55) 1.44 (1.86)
TC (mg/dl) 183.4 (32.1) 178.9 (28.3) 179.7 (33.4) 187.7 (25.2) 181.7 (30.7)
LDL-C (mg/dl) 113.1 (29.0) 108.6 (22.3) 110.2 (27.5) 118.3 (22.3) 111.5 (26.4)
HDL-C (mg/dl) 57.9 (10.6) 55.9 (11.6) 49.2 (9.4) 43.1 (8.1) 55.6 (11.4)
Low HDL - - - - 5%
TG (mg/dl) 62.4 (16.8) 72.0 (25.0) 101.5 (28.4) 131.3 (34.4) 72.9 (28.1)
Elevated TG - - - - 18%
Values are mean (SD) and % where indicated.
Figure 1 Metabolic syndrome score by the number of adverse
risk factors.
Table 3 Sensitivity and specificity of the continuous
metabolic syndrome score to identify children with the
metabolic syndrome.
Criterion Sensitivity (95% CI) Specificity (95% CI)
1.00 100 (81.3-100.0) 75.14 (70.3-79.5)
1.50 100 (81.3-100.0) 80.83 (76.4-84.8)
2.00 100.0 (81.3-100.0) 84.44 (80.3-88.0)
2.50 100.0 (81.3-100.0) 87.2 (83.3-90.5)
3.00 100.0 (81.3-100.0) 90.28 (86.7-93.1)
3.50 100.0 (81.3-100.0) 92.50 (89.3-95.0)
4.00 88.89 (65.2-98.3) 93.89 (90.9-96.1)
4.50 88.89 (65.2-98.3) 95.56 (92.9-97.4)
5.00 88.89 (65.2-98.3) 95.83 (93.2-97.6)
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-0.24 ± 1.16). Moreover, cMetS increased progressively
with increasing numbers of risk factors in men (0 risk
factors: -1.21 ± 0.96; 1 risk factor: -0.26 ± 0.87; 2 risk
factors: 0.67 ± 0.84; 3 risk factors: 1.76 ± 0.73; and 4
risk factors: 3.04 ± 0.94) and women (0 risk factors:
-0.96 ± 0.79; 1 risk factors: 0.16 ± 0.82; 2 risk factors:
1.21 ± 0.82; 3 risk factors: 2.17 ± 0.81; and 4 risk factors:
4.09 ± 0.99) [29]. These findings are similar to those
reported here and support the use of the cMetS in epi-
demiological analyses.
As previously mentioned, one limitation to this study
is that the MetS criteria - e.g., the Cook criteria - have
no clinical or health-related outcome basis. Recently,
age-specific criteria for the metabolic syndrome were
developed using the LMS statistical technique in 12-19
yr old subjects participating in the NHANES [44].
Unfortunately, we could not use these values since our
subjects were 7-9 yr old. The age of the subjects is both
a limitation and strength of the study. In terms of lim-
itations, the cMetS needs to be validated in older chil-
dren and adolescents. Another limitation is that the
cMetS is sample specific. If epidemiological studies are
to use the cMetS, a standardized method of calculating
the score may prove beneficial for comparing studies.
An alternative approach to the sample-specific Z score
Figure 2 Receiver operating characteristic curve for the continuous metabolic syndrome score as a predictor of metabolic syndrome
among 7-9 year old boys and girls. AUC = 0.978 (0.957-0.990, 95% confidence intervals).
Eisenmann et al. Diabetology & Metabolic Syndrome 2010, 2:8
http://www.dmsjournal.com/content/2/1/8
Page 6 of 8approach highlighted here may be to compare individual
risk factor value to the population median or clinical
cut-points such as those recently published [44].
In conclusion, this paper shows the convergent validity
for the cMetS that is becoming widely used in pediatric
epidemiological research. Furthermore, researchers can
use the approach herein to validate and create cMetS
that are specific to their study populations. It is recom-
mended that age-specific criteria for the metabolic syn-
drome such as those recently developed for 12-19 yr
olds be used as a criterion in future studies and that
such criteria be developed in younger children as well.
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